Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 2
2020 9
2021 12
2022 12
2023 12
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
The Arg/Arg genotype of leptin receptor gene Gln223Arg polymorphism may be an independent risk factor for nonalcoholic fatty liver disease.
Navari M, Zarei F, Sayedsalehi S, Mahmoudi T, Rostami M, Mahban A, Rezamand G, Asadi A, Dabiri R, Nobakht H, Farahani H, Tabaeian SP, Zali MR. Navari M, et al. Lab Med. 2024 Mar 24:lmae016. doi: 10.1093/labmed/lmae016. Online ahead of print. Lab Med. 2024. PMID: 38522074
BACKGROUND: Given that obesity and insulin resistance play key roles in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and the connection between leptin and these metabolic diseases, the association between NAFLD and a leptin receptor gene (LEPR) polym …
BACKGROUND: Given that obesity and insulin resistance play key roles in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) …
The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A.
Neshatbini Tehrani A, Hatami B, Helli B, Yari Z, Daftari G, Salehpour A, Hedayati M, Khalili E, Hosseini SA, Hekmatdoost A. Neshatbini Tehrani A, et al. Sci Rep. 2024 Mar 1;14(1):5134. doi: 10.1038/s41598-024-55747-6. Sci Rep. 2024. PMID: 38429385 Free PMC article. Clinical Trial.
A two-arm randomized open labeled controlled clinical trial was conducted on 50 patients with non-alcoholic fatty liver disease (NAFLD). Subjects were randomized to either receive two tablets of soy isoflavone (100 mg/day) or placebo. ...
A two-arm randomized open labeled controlled clinical trial was conducted on 50 patients with non-alcoholic fatty liver disease (NAFL …
The anti-inflammatory and anti-apoptotic effects of Achillea millefolium L. extracts on Clostridioides difficile ribotype 001 in human intestinal epithelial cells.
Raeisi H, Azimirad M, Asadi-Sanam S, Asadzadeh Aghdaei H, Yadegar A, Zali MR. Raeisi H, et al. BMC Complement Med Ther. 2024 Jan 13;24(1):37. doi: 10.1186/s12906-024-04335-2. BMC Complement Med Ther. 2024. PMID: 38218845 Free PMC article.
CONCLUSION: The results of the present study for the first time demonstrate the antimicrobial activity and protective effects of A. millefolium extracts on inflammatory response and apoptosis induced by Tox-S from C. difficile RT001 clinical strain in vitro. Further research …
CONCLUSION: The results of the present study for the first time demonstrate the antimicrobial activity and protective effects of A. millefol …
Development of solid lipid nanoparticles-loaded drugs in parasitic diseases.
Nemati S, Mottaghi M, Karami P, Mirjalali H. Nemati S, et al. Discov Nano. 2024 Jan 4;19(1):7. doi: 10.1186/s11671-023-03955-w. Discov Nano. 2024. PMID: 38175309 Free PMC article. Review.
This review describes development of SLNs, the methods of preparation, characterization, and loaded drugs into SLNs in parasitic diseases. In addition, we summarize recent development in anti-parasitic SLNs-loaded drugs....
This review describes development of SLNs, the methods of preparation, characterization, and loaded drugs into SLNs in parasitic diseases …
Characterization of gut microbiome composition in Iranian patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Abdollahiyan S, Nabavi-Rad A, Keshavarz Azizi Raftar S, Monnoye M, Salarieh N, Farahanie A, Asadzadeh Aghdaei H, Zali MR, Hatami B, Gérard P, Yadegar A. Abdollahiyan S, et al. Sci Rep. 2023 Nov 23;13(1):20584. doi: 10.1038/s41598-023-47905-z. Sci Rep. 2023. PMID: 37996480 Free PMC article.
Gut microbiota dysbiosis is intimately associated with development of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Nevertheless, the gut microbial community during the course of NAFLD and NASH is yet to be comprehensively profiled. ...
Gut microbiota dysbiosis is intimately associated with development of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic stea …
51 results